Your Messages Inbox
Your Article Summary
See Latest ArticlesMedtronic's CoreValve Shows Subclavian Access Success in Patients Contraindicated for Femoral Approach
Medtronic, 06/02/09
Medtronic, Inc. announced new data presented on the safety and effectiveness of Medtronic's CoreValve system via a novel, subclavian approach. The data reported procedural success of 100 percent; 24-hour survival of 100 percent; and 30-day survival of 89 percent. The available 30-day analysis also demonstrated clinical improvement in heart failure symptoms with 76 percent of the patients gaining at least a one-stage NYHA class and one-third improving by at least two stages.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09
Reports Rate Ambulatory EHR Software
HealthDataManagement, 11/25/09
Article Search
Sponsor